SMX18-001

An open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of Pre- and Post-Menopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. (ELAINE)

SMX18-001: An open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of Pre- and Post-Menopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. (ELAINE)

The purpose of this study is to compare the effects of fulvestrant to the effects of lasofoxifine in breast cancer. The study will determine if the time to progression while receiving lasofoxifine improves compared to fulvestrant without increasing side effects.

In addition, this study will gather information about the effects of each drug on certain aspects of quality of life.

Principal Investigator

Cengiz Inal, MD

Contact

Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]

Locations

Peninsula Cancer Institute
12100 Warwick Blvd, Suite 201
Newport News, VA 23601

Status

Recruiting